Stock Analiz

RenovoRx, Inc. RNXT

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$1.04Market cap $50M
Open the interactive analysis →

RenovoRx, Inc. (RNXT) is a healthcare company listed in the US with a market value of about $50M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$13M, a net margin of -469.0%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -163%.

About RenovoRx

RenovoRx is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 290% over three years (dilution for shareholders). It spends 558% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S18.1
P/B5.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-24.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)2511.6%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-10746.1%
ROIC (5-yr avg.)-162.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$3M$1M$43000————
Net income-$13M-$11M-$9M-$10M-$10M-$6M-$4M
Free cash flow-$12M-$11M-$9M————
EPS (diluted)$-0.31$-0.32$-0.40$-0.99$-1.09$-1.21$-1.72
Net margin-469.0%-994.5%-20497.7%————
ROIC—-175.4%-182.2%-300.1%-127.5%-29.1%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does RenovoRx pay a dividend?

Not currently.

Is RenovoRx a good stock to buy?

We do not give buy or sell advice. RenovoRx scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.